---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-038472"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2024-08-26T23:59:59+00:00"
generated_at: "2026-05-31T07:46:21.385732+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FDA approves Vericel's MACI Arthro for arthroscopic knee cartilage repair

## Summary
- FDA approved sBLA for arthroscopic delivery of MACI (MACI Arthro) to repair knee defects up to 4 cm².
- MACI Arthro targets largest segment of $3B addressable market: ~20,000 patients/year with 2-4 cm² femoral condyle defects.
- Vericel expanding target surgeon base from 5,000 to 7,000 to include high-volume arthroscopic cartilage repair surgeons.
- MACI is first FDA-approved cellularized scaffold and first restorative biologic approved for arthroscopic administration.
- CEO Nick Colangelo: approval supports sustained top-tier revenue growth.

## SEC filing metadata
- accession: 0001140361-24-038472
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2024-08-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000114036124038472/0001140361-24-038472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000114036124038472/ef20034807_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-038472
- JSON: https://secwatch.observer/filing/0001140361-24-038472.json
- Plain text: https://secwatch.observer/filing/0001140361-24-038472.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.